4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals

Clinical and Experimental Metastasis

Volumn 16, Issue 7, 1998, Pages 633-643

  Murakami, Koji ^a,b   Matsuura, Tomokazu ^c   Sano, Masaki ^b   Hashimoto, Akihiro ^b   Yonekura, Kazuhiko ^b   Sakukawa, Rieko ^a   Yamada, Yuji ^b   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Hepatocellular carcinoma; Invasion; JHH 7; TAC 101

Indexed keywords

4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDE]; 4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDO]BENZOIC ACID; BENZOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL SPREADING; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG RECEPTOR BINDING; LIFESPAN; LIGAND BINDING; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; RECEPTOR DOWN REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZOATES; BODY WEIGHT; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, RETINOIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECIFIC PATHOGEN-FREE ORGANISMS; SURVIVAL RATE; TRIMETHYLSILYL COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0343979588     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006567229929     Document Type: Article

References (45)

1. 1. Carr BI, Fliinger JC and Lotze MT, 1997, Hepato-biliary cancers. In: Caputo GR, ed, Cancer Principles & Practice of Oncology 5th. edn., 1, 1087-114.
2. 2. Okuda K, Ohtsuki T, Obata H, et al., 1985, Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer, 56, 918-28.
3. 3. Ryu M, Shimamura Y, Kinoshita T, et al., 1997, Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn J Clin Oncol, 27, 251-7.
4. 4. Lin DY, Lin SM and Liaw YF, 1997, Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol, 12, S319-S328.
5. 5. Ebara M, Ohto M, Sugiura N, et al., 1990, Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: study of 95 patients. J Gastroenterol Hepatol, 5, 616-26.
6. 6. Hashimoto T, Nakayama S, Fukkuhara T, et al., 1994, The state of recurrence and the role of hepatectomy in hepatocellular carcinoma. Hepatogastroenterology, 41, 144-9.
7. 7. Kumada T, Nakano S, Takeda I, et al., 1997, Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology, 25, 87-92.
8. 8. Hu RH, Lee PH, Yu SC, et al., 1996, Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery, 120, 23-9.
9. 9. Sun SY, Yue P, Dawson MI, et al., 1997, Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res, 57, 4931-9.
10. 10. David JM, Umezono K and Evans RM, 1994, The retinoic acid receptors. In: Sporn MB, Roberts AB and Goodman DS, eds, The Retinoids : Biology, Chemistry, and Medicine, 2nd edn. Raven Press: New York, pp 319-49.
11. 11. Zhang LX, Mills KJ, Dawson MI, et al., 1995, Evidence for the involvement of retinoic acid receptor RAR alpha-dependent signaling pathway in the induction of tissue transglutaminase and apoptosis by retinoids. J Biol Chem, 270, 6022-9.
12. 12. Pollard M and Luckert PH, 1991, The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats. Cancer Lett, 59, 159-63.
13. 13. Oikawa T, Okayasu I, Ashino H, et al., 1993, Three novel synthetic retinoids, Re80, Am580, Am80, all exhibit anti-angiogenic activity in vivo. Eur J Pharmacol, 249, 113-16.
14. 14. Murakami K, Wierzba K, Sano M, et al., 1998, TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. Clin Experimental Metastasis, 16, 323-31.
15. 15. Sever CE and Locker J, 1991, Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol Carcinog, 4, 138-44.
16. 16. Nomura T, Sakurai Y and Inaba M, 1996, Detection of clinically equivalent doses In: The Nude Mouse and Anticancer Drug Evaluation. Chemotherapy Publishers Inc. pp 29-52.
17. 17. Utsugi T, Aoyagi K, Asao T, et al., 1997, Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res, 88, 992-1002.
18. 18. Bernhardt G, Reile H, Birnbock H, et al., 1992, Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol, 118, 35-43.
19. 19. Ishida Y, Agata Y, Shibahara K and Honjo T, 1992, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J, 11, 3887-95.
20. 20. Saito K, Ata N, Miyashiro H, et al., 1997, A modified and convenient method for assessing tumor cell invasion and migration and its application to screening for inhibitors. Biol Pharm Bull, 20, 345-8.
21. 21. Borset M, Lien E, Espevik T, et al., 1996, Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem, 271, 24655-61.
22. 22. McArdle BH, 1987, The significance of differences between means A simulation study. Comp Biochem Physiol A, 87, 979-82.
23. 23. Hilton JF, 1996, The appropriateness of the Wilcoxon test in ordinal data. Stat Med, 30, 631-45.
24. 24. Hochberg Y and Tamhane AC, 1987, 12 Multivariate t-distribution. In: Multiple Comparison Procedures, New York: John Wiley & Sons, pp 374-5.
25. 25. Hashimoto Y, Kagechika H, Kawachi E, et al., 1996, Evaluation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. Biol Pharm Bull, 19, 1322-8.
26. 26. Horn V, Minucci S, Ogryzko VV, et al., 1996, RAR and RXR selective ligands cooperatively induce apoptosis and neuronal differentiation in P19 embryonal carcinoma cells embryonal carcinoma cells. FASEB J., 10, 1071-7.
27. 27. Lu XP, Fanjul A, Picard N, et al., 1997, Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat Med, 3, 686-90.
28. 28. Kaji M, Yonemura Y, Harada S, et al., 1996, Participation of c-MET in the progression of human gastric cancers: anti-c-MET oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther, 3, 393-404.
29. 29. Uchiyama A, Essner R, Doi F, et al., 1996, Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas. J Cell Biochem, 62, 443-53.
30. 30. de Grazia U, Felli MP, Vacca A, et al., 1994, Positive and negative regulation of the composite octamer motif of the interleukin 2 enhancer by AP-1, Oct-2, and retinoic acid receptor. J Exp Med, 180, 1485-97.
31. 31. Mattei MG, Petkovich M, Mattei JF, et al., 1988, Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet, 80, 186-8.
32. 32. Simon D, David P, Knowles AB and Knowles BB, 1982, Chromosomes of human hepatoma cell lines. Int J Cancer, 30, 27-33.
33. 33. Marchio A, Meddeb M, Pineau P, et al., 1997, Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer, 18, 59-65.
34. 34. Bottaro DP, Rubin JS, Faletto DL, et al., 1991, Identification of the hepatocyte growth factor receptor as the c-MET proto-oncogene product. Science, 251, 802-4.
35. 35. Matsumoto K and Nakamura T, 1991, Hepatocyte growth factor: molecular structure and implications for a central role in liver regeneration. J Gastroenterol Hepatol, 6, 509-19.
36. 36. Sakata H, Takayama H, Sharp R, et al., 1996, Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ, 7, 1513-23.
37. 37. Bussolino F, Di Renzo MF, Ziche M, et al., 1992, Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol, 119, 629-41.
38. 38. Bhargava M, Joseph A, Knesel J, et al., 1992, Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ, 3, 11-20.
39. 39. Ueki J, Fujimoto J, Suzuki T, et al., 1997, Expression of Hepatocyte growth factor and its receptor c-MET proto-oncogene in hepatocellular carcinoma. Hepatology, 25, 862-6.
40. 40. Schule R, Rangarajan P, Yang N, et al., 1991, Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci USA, 88, 6092-6.
41. 41. Nagpal S, Cai J, Zheng T, et al., 1997, Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mol Cell Biol, 17, 4159-68.
42. 42. Smarda J, Sugarman J, Glass C and Lipsick J, 1995, Retinoic acid receptor alpha suppresses transformation by v-myb. Mol Cell Biol, 15, 2474-81.
43. 43. de Grazia U, Felli MP, Vacca A, et al., 1994, Positive and negative regulation of the composite octamer motif of the interleukin 2 enhancer by AP-1, Oct-2, and retinoic acid receptor. J Exp Med, 180, 1485-97.
44. 44. Cheng X, Reginato MJ, Andrews NC and Lazar MA, 1997, The transcriptional integrator CREB-binding protein mediates positive cross talk between nuclear hormone receptors and the hematopoietic bZip protein p45/NF-E2. Mol Cell Biol, 17, 1407-16.
45. 45. Nakamura T, Nishizawa T, Hagiya M, et al., 1989, Molecular cloning and expression of human hepatocyte growth factor. Nature, 23, 440-3.